


Claims

- 1 A compound of formula (I), a pharmaceutically acceptable salt, solvate or derivative thereof;

5



(I)

wherein

either a) A is C(R²) and D is N; or b) A is N and D is C(R²);

R¹ is selected from the list: hydrogen, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkoxy, halo, cyano, perfluoro C₁₋₆alkyl, perfluoro C₁₋₆alkoxy, -NR³R⁴, -(CH₂)_nNR³R⁴, -O(CH₂)_nOR⁵, -O(CH₂)_nNR³R⁴, -O(CH₂)_nHet, -CONR³R⁴, -CO(CH₂)_nNR³R⁴, -SO₂R⁵, -SO₂NR³R⁴, -NR³SO₂R⁵, -NR³COR⁵, -NR³CO(CH₂)_nNR³R⁴, Het and -O(CH₂)_nCONR³R⁴;

R² is hydrogen or C₁₋₄alkyl;

R³ and R⁴ are independently hydrogen, C₁₋₆alkyl, Het or C₁₋₄alkoxyC₁₋₄alkyl; or R³ and R⁴ together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7-membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), -CN, -CF₃, -OH, -OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy;

R⁵ is hydrogen or C₁₋₆alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C₁₋₆alkyl; and

n is 1-4.

10

15

20

25

- 2 A compound according to claim 1 wherein R¹ is C₁₋₆alkoxy, halo, cyano, perfluoroC₁₋₆alkoxy, -NR³R⁴, -(CH₂)_nNR³R⁴, -O(CH₂)_nNR³R⁴, -O(CH₂)_nHet, -CONR³R⁴, -SO₂R⁵, -NR³CO(CH₂)_nNR³R⁴, Het or -O(CH₂)_nCONR³R⁴.
- 5 3 A compound according to any preceding claim wherein R³ and R⁴ are independently hydrogen, methyl, Het or C₁₋₄alkoxyC₁₋₄alkyl; or R³ and R⁴ together with the atom to which they are attached form a morpholine, piperidine, pyrrolidine or piperazine ring.
- 10 4 A compound according to any preceding claim wherein either a) A is C(R²) and D is N; or b) A is N and D is C(R²); R¹ is C₁₋₆alkoxy, halo, cyano, perfluoroC₁₋₆alkoxy, -NR³R⁴, -(CH₂)_nNR³R⁴, -O(CH₂)_nNR³R⁴, -O(CH₂)_nHet, -CONR³R⁴, -SO₂R⁵, -NR³CO(CH₂)_nNR³R⁴, Het or -O(CH₂)_nCONR³R⁴;
- 15 R² is hydrogen or methyl;
- R³ and R⁴ are independently hydrogen, methyl, Het or C₁₋₄alkoxyC₁₋₄alkyl; or R³ and R⁴ together with the nitrogen atom to which they are attached form a morpholine, piperidine, pyrrolidine or piperazine ring, which ring may be further substituted by one or more substituents selected
- 20 from halo -CN, -CF₃, -OH, -OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy;
- R⁵ is hydrogen or C₁₋₆alkyl;
- Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by
- 25 C₁₋₆alkyl; and
- n is 1-3.
- 5 A compound according to claim 1 selected from the list:
- 30 2-{4-(1-methyl-imidazol-4-yl)methoxy}-phenyl-4-(3-(6-methyl-pyridin-2-yl)-1H-pyrazol-4-yl)pyridine (Example 1) ;
- 2-[4-(ethylsulfonyl)phenyl]-4-[3-(6-methyl-pyridin-2-yl)-1H-pyrazol-4-yl]pyridine (Example 2);
- 4-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]-2-[4-(pyrrolidin-1-ylmethyl)phenyl]pyridine (Example 3);
- 35 4-(4-{4-[5-methyl-3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzyl)morpholine (Example 7); and

3-[2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyridin-4-yl]-4-[6-methylpyridin-2-yl]-
1H-pyrazole (Example 22);
and pharmaceutically acceptable salts, solvates and derivatives thereof.

- 5 6 A pharmaceutical composition comprising a compound defined in any
preceding claim and a pharmaceutically acceptable carrier or diluent.
- 7 The use of a compound defined in any one of claims 1 to 5 in the
10 manufacture of a medicament for the treatment or prophylaxis of a disorder
mediated by the ALK5 receptor in mammals.
- 8 The use according to claim 7 wherein the disorder is selected from chronic
renal disease, acute renal disease, wound healing, arthritis, osteoporosis,
15 kidney disease, congestive heart failure, ulcers, ocular disorders, corneal
wounds, diabetic nephropathy, impaired neurological function, Alzheimer's
disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease
wherein fibrosis is a major component, including, but not limited to lung
fibrosis, kidney fibrosis, liver fibrosis [for example, hepatitis B virus (HBV),
20 hepatitis C virus (HCV)], alcohol induced hepatitis, retroperitoneal fibrosis,
mesenteric fibrosis, haemochromatosis and primary biliary cirrhosis,
endometriosis, keloids and restenosis.
- 9 The use according to claim 8 wherein the disorder is kidney fibrosis.
- 25 10 A compound defined in any one of claims 1 to 5 for use as a medicament.